FDA approves new treatment for rare form of hemophilia
The FDA approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency). Obizur is manufactured by Baxter Healthcare Corporation, Westlake Village, California. October 24, 2014